|
| 特征 |
低股价和低NLR (n= 145) |
低PLC或低NLR (n= 351) |
高股价、高NLR (n= 141) |
|
|
| 年龄、年 |
72.40±5.28 |
71.95±5.20 |
72.31±4.83 |
0.615 |
| 性别(男),n(%) |
105 (72.41) |
227 (64.67) |
85 (60.28) |
0.088 |
| 抽烟和喝酒,n(%) |
59 (40.69) |
140 (39.89) |
54 (38.30) |
0.914 |
| 高血压,n(%) |
85 (58.62) |
205 (58.40) |
89 (63.12) |
0.610 |
| 冠心病之前,n(%) |
23日(15.86) |
37 (10.54) |
12 (8.51) |
0.116 |
| 糖尿病,n(%) |
35 (24.14) |
93 (26.50) |
38 (26.95) |
0.831 |
| 中风,n(%) |
15 (10.34) |
54 (15.38) |
16 (11.35) |
0.237 |
| SBP入院时(毫米汞柱) |
130.99±24.30 |
130.01±24.07 |
125.53±25.94 |
0.117 |
| 菲律宾入院时(毫米汞柱) |
75.18±14.22 |
75.61±14.09 |
74.77±16.14 |
0.806 |
| 人力资源在入学(次/分钟) |
73.43±11.25 |
77.08±15.59 |
82.74±19.67 |
< 0.001 |
| 痛苦再灌注(h) |
16.70±8.14 |
14.16±8.99 |
12.32±8.27 |
< 0.001 |
| 住院一天 |
8.28±5.12 |
8.44±6.43 |
10.21±9.50 |
0.024 |
| Killip类、iii ivn(%) |
11 (7.59) |
50 (14.25) |
37 (26.24) |
< 0.001 |
| 诊断 |
| STEMI |
57 (39.31) |
209 (59.54) |
95 (67.38) |
< 0.001 |
| NSTEMI |
88 (60.69) |
142 (40.46) |
46 (32.62) |
< 0.001 |
| LVEF (%) |
55.86±12.33 |
52.72±12.21 |
49.92±12.27 |
< 0.001 |
| 肌酐(μ摩尔/升) |
87.10±26.91 |
92.98±39.34 |
93.60±35.44 |
0.202 |
| AST (u / l) |
55.45±68.72 |
90.26±106.13 |
136.06±129.10 |
< 0.001 |
| ALT (u / l) |
28.68±39.30 |
36.15±37.78 |
43.52±44.94 |
0.007 |
| 中位数水平以上病人(pg / ml) |
3863.64±6575.65 |
4813.60±7299.85 |
5702.91±11031.69 |
0.161 |
| CTnI (pg / ml) |
10058.40±15443.85 |
14747.61±18692.72 |
22783.39±20504.55 |
< 0.001 |
| 高密度脂蛋白(更易/ l) |
1.09±0.41 |
1.08±0.44 |
1.17±0.50 |
0.124 |
| 低密度脂蛋白(更易/ l) |
2.52±0.92 |
2.52±0.92 |
2.79±1.09 |
0.012 |
| 总甘油三酸酯(更易/ l) |
1.36±0.81 |
1.39±1.09 |
1.20±1.08 |
0.169 |
| 总胆固醇(更易/ l) |
4.00±1.07 |
4.04±1.09 |
4.42±1.25 |
0.001 |
| 白细胞计数(109/ l) |
6.97±2.35 |
9.00±3.19 |
12.37±4.58 |
< 0.001 |
| PLC (109/ l) |
153.80±26.76 |
201.10±65.48 |
258.08±62.10 |
< 0.001 |
| 嗜中性粒细胞计数(109/ l) |
4.62±1.86 |
6.97±3.32 |
10.70±4.29 |
< 0.001 |
| 淋巴细胞计数(109/ l) |
1.67±0.63 |
1.42±0.68 |
1.02±0.47 |
< 0.001 |
| 单核细胞计数(109/ l) |
0.52±0.20 |
0.56±0.28 |
0.61±0.39 |
0.025 |
| 血红蛋白(mg / dl) |
129.19±18.56 |
126.94±19.25 |
123.43±17.86 |
0.033 |
| NLR |
2.92±1.03 |
6.61±6.35 |
12.29±7.17 |
< 0.001 |
| 药物在医院,n (%) |
| 阿斯匹林 |
140 (96.55) |
338 (96.30) |
132 (93.62) |
0.356 |
| 氯吡格雷 |
135 (93.10) |
337 (96.01) |
131 (92.91) |
0.244 |
| β受体阻滞剂 |
108 (74.48) |
250 (71.23) |
94 (66.67) |
0.342 |
| ACEI / ARB |
109 (75.17) |
244 (69.52) |
92 (65.25) |
0.184 |
| 他汀类药物 |
144 (99.31) |
343 (97.72) |
136 (96.45) |
0.254 |
|
|
|
意味着±SD和n(%)报告连续和分类变量,分别。缩写:SD,标准偏差;PLC)、血小板计数;NLR neutrophil-to-lymphocyte比率;COP-NLR,血小板计数和neutrophil-to-lymphocyte比率;冠心病、冠心病;SBP收缩压;菲律宾,舒张压;人力资源、心率;STEMI的st段抬高心肌梗死; NSTEMI, non-ST-elevation myocardial infarction; LVEF, left ventricular ejection fraction; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NT-proBNP, N-terminal probrain natriuretic peptide; CTnI, cardiac troponin I; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; WBC, white blood cell; SII, systemic immune-inflammatory index; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.
|
